Recently, TIMD4 blockade has been proposed as a potential strategy to enhance the efficacy of CD8+ T cell‐based immunotherapies in cancers such as melanoma and lung cancer [56, 57]. The gene discussed is CD8A; the disease is lung carcinoma.